Immature platelets in patients with acute coronary syndromes

Erik Lerkevang Grove; Anne-Mette Hvas; Steen Dalby Kristensen

doi:10.1160/TH08-03-0186

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2009; 101(01): 151-153
DOI: 10.1160/TH08-03-0186

Cardiovascular Biology and Cell Signalling

Schattauer GmbH

Immature platelets in patients with acute coronary syndromes

Erik Lerkevang Grove

¹Department of Cardiology, Aarhus University Hospital Skejby, Aarhus N, Denmark

,

Anne-Mette Hvas

²Department of Clinical Biochemistry, Centre for Haemophilia and Thrombosis, Aarhus University Hospital Skejby, Aarhus N, Denmark

,

Steen Dalby Kristensen

¹Department of Cardiology, Aarhus University Hospital Skejby, Aarhus N, Denmark

› Institutsangaben

Abstract

Summary

Platelets newly released from the bone marrow are RNA-containing and more haemostatically active than mature platelets. Immature platelets are reliably quantified by flow cytometry, and the immature platelet fraction (IPF) reflects platelet production and the rate of platelet turnover. It was the objective of this study to evaluate the presence of immature platelets in healthy subjects, patients with stable coronary artery disease (CAD) and patients with acute coronary syndromes. Flow cytometric determination of immature platelets was performed with an automated analyzer (Sysmex XE-2100) using RNA fluorescent dyes. IPF was determined in 420 individuals: 22 healthy subjects, 39 patients with stable CAD, 182 patients with unstable angina/ non-ST-segment elevation myocardial infarction (non-STEMI) and 177 patients with acute STEMI. The geometric mean [95% confidence interval] of IPF was 2.51 [2.04–3.10] in healthy subjects, 2.87 [2.45–3.36] in CAD patients, 2.93 [2.72–3.15] in the non-STEMI/unstable angina group and 3.71 [3.45–3.99] in patients with STEMI (ANOVA: p < 0.0001). This difference remained significant after adjusting for baseline characteristics (p = 0.0003). In active smokers, IPF was 18% higher than in non-smoking individuals (p = 0.007), and IPF was 16% higher in diabetics compared with non-diabetics (p = 0.060). In conclusion, the fraction of immature platelets is increased in acute coronary syndromes, especially in the acute phase of STEMI. Immature platelets with an increased haemostatic potential may contribute to coronary thrombus formation.

Keywords

Atherothrombosis - arterial thrombosis - aspirin resistance - myocardial infarction - thrombopoiesis

Volltext

Referenzen

References
1 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
2 Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 2005; 03: 1597-1602.
3 Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007; 115: 2196-2207.
4 Snoep JD, Hovens MM, Eikenboom JC. et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599.
5 Marcucci R, Paniccia R, Antonucci E. et al. Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. Thromb Haemost 2007; 98: 844-851.
6 Krasopoulos G, Brister SJ, Beattie WS. et al. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198.
7 Thompson CB, Eaton KA, Princiotta SM. et al. Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and function. Br J Haematol 1982; 50: 509-519.
8 Brown AS, Martin JF. The megakaryocyte platelet system and vascular disease. Eur J Clin Invest 1994; 24 (Suppl. 01) 9-15.
9 Martin JF, Trowbridge EA, Salmon G. et al. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1983; 32: 443-460.
10 Martin JF, Plumb J, Kilbey RS. et al. Changes in volume and density of platelets in myocardial infarction. Br Med J (Clin Res Ed) 1983; 287: 456-459.
11 Milner PC, Martin JF. Shortened bleeding time in acute myocardial infarction and its relation to platelet mass. Br Med J (Clin Res Ed) 1985; 290: 1767-1770.
12 Kristensen SD, Bath PM, Martin JF. Differences in bleeding time, aspirin sensitivity and adrenaline between acute myocardial infarction and unstable angina. Cardiovasc Res 1990; 24: 19-23.
13 Ault KA, Rinder HM, Mitchell J. et al. The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. Am J Clin Pathol 1992; 98: 637-646.
14 Briggs C, Kunka S, Hart D. et al. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol 2004; 126: 93-99.
15 Kieffer N, Guichard J, Farcet JP. et al. Biosynthesis of major platelet proteins in human blood platelets. Eur J Biochem 1987; 164: 189-195.
16 Guthikonda S, Lev EI, Patel R. et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007; 05: 490-496.
17 Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606-617.
18 Harrison P, Mackie I, Mathur A. et al. Platelet hyper-function in acute coronary syndromes. Blood Coagul Fibrinolysis 2005; 16: 557-562.
19 Briggs C, Hart D, Kunka S. et al. Immature platelet fraction measurement: a future guide to platelet transfusion requirement after haematopoietic stem cell transplantation. Transfus Med 2006; 16: 101-109.
20 Briggs C, Kunka S, Machin SJ. The most accurate platelet count on the Sysmex XE-2100. Optical or impedance? Clin Lab Haematol 2004; 26: 157-158.
21 Bland JM, Altman DG. Transforming data. Br Med J 1996; 312: 770.
22 Rocca B, Secchiero P, Ciabattoni G. et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002; 99: 7634-7639.
23 Guthikonda S, Mangalpally K, Vaduganathan M. et al. Increased platelet sensitivity among individuals with aspirin resistance – Platelet aggregation to sub-maximal concentration of arachidonic acid predicts response to antiplatelet therapy. Thromb Haemost 2008; 100: 83-89.
24 Cesari F, Marcucci R, Caporale R. et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008; 99: 930-935.
25 Lakkis N, Dokainish H, Abuzahra M. et al. Reticulated platelets in acute coronary syndrome: a marker of platelet activity. J Am Coll Cardiol 2004; 44: 2091-2093.
26 Kickler TS, Oguni S, Borowitz MJ. A clinical evaluation of high fluorescent platelet fraction percentage in thrombocytopenia. Am J Clin Pathol 2006; 125: 282-287.
27 Fitzgerald DJ, Roy L, Catella F. et al. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-989.
28 Poulsen TS, Kristensen SR, Korsholm L. et al. Variation and importance of aspirin resistance in patients with known cardiovascular disease. Thromb Res 2007; 120: 477-484.
29 Valles J, Santos MT, Fuset MP. et al. Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2007; 99: 19-25.
30 Perneby C, Wallen NH, Rooney C. et al. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652-658.
31 van Werkum JW, Topcu Y, Postma S. et al. Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel. Thromb Haemost 2008; 99: 637-639.
32 Watala C, Boncler M, Pietrucha T. et al. Possible mechanisms of the altered platelet volume distribution in type 2 diabetes: does increased platelet activation contribute to platelet size heterogeneity?. Platelets 1999; 10: 52-60.
33 Watala C, Boncler M, Gresner P. Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep 2005; 57 Suppl 42-58.
34 Shantsila E, Lip GY. Beyond glucose levels in diabetic patients with coronary artery disease: Platelet activity and non-responsiveness to antiplatelet therapy. Thromb Haemost 2008; 100: 7-8.
35 Serebruany V, Pokov I, Kuliczkowski W. et al. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008; 100: 76-82.
36 DiChiara J, Bliden KP, Tantry US. et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 2007; 56: 3014-3019.
37 Angiolillo DJ, Bernardo E, Sabate M. et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007; 50: 1541-1547.
38 Sideris G, Guyetand C, Belluci S. et al. Low dose aspirin does not maintain a 24-hour biological efficacy in type-2 diabetic patients. Eur Heart J 2007; 28 Suppl 267.
39 Frossard M, Fuchs I, Leitner JM. et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004; 110: 1392-1397.
40 Borna C, Lazarowski E, van HC. et al. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J 2005; 03: 10.